Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States

Generic entry of newer anticoagulants is expected to decrease the costs of atrial fibrillation management. However, when making switches between brand and generic medications, bioequivalence concerns are possible. The objectives of this study were to predict and compare the lifetime cost‐effectivene...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ching‐Yu Wang (Autor), Phuong N. Pham (Autor), Sarah Kim (Autor), Karthik Lingineni (Autor), Stephan Schmidt (Autor), Vakaramoko Diaby (Autor), Joshua Brown (Autor)
Formato: Libro
Publicado: Wiley, 2020-03-01T00:00:00Z.
Materias:
Acceso en línea:Connect to this object online.
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

Connect to this object online.

3rd Floor Main Library

Detalle de Existencias desde 3rd Floor Main Library
Número de Clasificación: A1234.567
Copia 1 Disponible